Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Centaurus Financial Inc.

Centaurus Financial Inc. trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 8.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,335 shares of the company’s stock after selling 608 shares during the quarter. Centaurus Financial Inc.’s holdings in Moderna were worth $752,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Profund Advisors LLC raised its holdings in shares of Moderna by 20.9% in the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after buying an additional 9,719 shares during the period. Marshall Wace LLP grew its position in Moderna by 295.5% in the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock valued at $4,180,000 after acquiring an additional 26,300 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Moderna during the second quarter worth about $4,036,000. Teachers Retirement System of The State of Kentucky lifted its position in shares of Moderna by 4.3% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 283,909 shares of the company’s stock worth $33,714,000 after purchasing an additional 11,828 shares in the last quarter. Finally, Hobbs Group Advisors LLC purchased a new position in shares of Moderna in the fourth quarter valued at approximately $664,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. JPMorgan Chase & Co. cut Moderna from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $88.00 to $70.00 in a research note on Friday, September 13th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, September 13th. Barclays cut their price target on Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a report on Monday, September 16th. Finally, HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $100.44.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,158 shares of company stock valued at $9,259,012 over the last three months. 15.70% of the stock is currently owned by company insiders.

Moderna Trading Down 1.4 %

NASDAQ MRNA opened at $60.20 on Friday. The firm’s fifty day moving average is $78.45 and its two-hundred day moving average is $107.98. Moderna, Inc. has a one year low of $59.62 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The firm has a market cap of $23.07 billion, a PE ratio of -3.84 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the firm posted ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.86 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.